Recent developments include Jasper Therapeutics securing $132 million in financing to advance its clinical pipeline post-Kira acquisition, completing the Kira acquisition with plans for multiple clinical milestones through 2027, and reporting positive clinical data for briquilimab in allergic asthma and urticaria studies.

• Jasper Therapeutics secured $132 million in financing to support advancement of its post-Kira clinical pipeline [N1].
• The company completed the acquisition of Kira Pharmaceuticals in July 2026 and is targeting multiple clinical milestones through 2027 [N2].
• Jasper reported positive results for briquilimab in a Phase 1b allergic asthma study, demonstrating proof-of-concept [N4].
• The company hosted a webinar to present results from the BEACON and ETESIAN studies, highlighting clinical progress [N5].
• RBC Capital maintained a Sector Perform recommendation on Jasper Therapeutics as of November 2025 [N6].
• Jasper conducted a $29.6 million underwritten public offering in September 2025 to raise capital for operations and development [N8].

Jasper Therapeutics has demonstrated positive clinical data for briquilimab in multiple mast cell driven diseases, including CSU, CIndU, and asthma, with evidence of rapid and durable clinical responses and a favorable safety profile. The company’s recent $132 million financing and completion of the Kira acquisition provide capital and expanded pipeline opportunities. Exclusive licensing agreements with Amgen and Stanford University support proprietary development. If clinical development continues to progress successfully, Jasper could establish a differentiated position in mast cell therapeutics with potential for multiple indications.

Jasper Therapeutics faces significant risks including its history of net losses, negative cash flows, and substantial doubt about its ability to continue as a going concern without additional financing. The integration of Kira Pharmaceuticals poses operational and financial challenges that could disrupt business and delay anticipated benefits. Clinical development risks include potential failure to demonstrate efficacy or safety in ongoing trials, regulatory hurdles, and competitive pressures. The company’s reliance on external financing and the uncertainty of achieving regulatory approvals and commercialization add to the risk profile.

Jasper Therapeutics’ moat is based on its proprietary monoclonal antibody briquilimab, which targets the SCF/KIT pathway to deplete mast cells, a novel mechanism in mast cell driven diseases. The company holds exclusive global licenses from Amgen and Stanford University, providing intellectual property protection and development rights. Its clinical-stage pipeline with multiple ongoing trials and positive preliminary data supports its position in a niche therapeutic area with unmet medical needs. However, as a clinical-stage biotech, the moat is contingent on successful clinical development, regulatory approvals, and commercialization capabilities, which remain uncertain and competitive.

• Integration Risks: The acquisition of Kira Pharmaceuticals involves complex integration challenges, including potential loss of key employees, operational disruptions, and increased expenses, which could adversely affect financial results and business prospects [S2].
• Financial Sustainability: Jasper has incurred significant losses and negative cash flows with an accumulated deficit of $320.6 million as of June 30, 2026, raising substantial doubt about its ability to continue as a going concern without additional capital [S2].
• Clinical Development Risks: The company’s lead product candidate briquilimab is in early clinical stages with inherent risks of failure to demonstrate safety and efficacy, potential delays, or regulatory setbacks [S1].
• Dependence on Financing: Jasper requires substantial additional funding to continue operations and clinical development. Failure to secure financing on acceptable terms could force delays or reductions in development programs [S2][N1].
• Regulatory and Market Risks: Uncertainty exists regarding regulatory approvals, competitive landscape, and market acceptance of briquilimab and other product candidates [S1][S2].

• Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and asthma, with ongoing evaluation of additional mast cell driven indications [S1].
• The company has discontinued prior programs targeting diseased hemopoietic stem cells and is now exclusively focused on mast cell driven diseases [S1].
• Its lead product candidate is briquilimab, a humanized monoclonal antibody designed to block stem cell factor (SCF) from binding to the CD117 (KIT) receptor on mast and stem cells, aiming to deplete mast cells and provide clinical benefit in mast cell driven diseases [S1].
• Briquilimab has been studied in multiple clinical trials: the Phase 1b/2a BEACON study in CSU, the Phase 1b/2a SPOTLIGHT study in CIndU, an Open Label Extension (OLE) study, and the Phase 1b ETESIAN study in asthma [S1].
• BEACON study data showed rapid onset of clinical efficacy with responses as early as 1 week post-dose and complete responses by week 2, with strong efficacy at doses of 180mg or higher and a favorable safety profile characterized by generally transient, low-grade KIT-related adverse events [S1].
• An investigation into atypical efficacy results in certain BEACON cohorts attributed the issue to patient selection criteria at some clinical sites rather than product quality, with subsequent data supporting the effectiveness of revised enrollment criteria [S1].
• SPOTLIGHT study in CIndU showed 96% of participants achieving clinical response within 8 weeks and 88% achieving complete response at higher doses, with briquilimab well tolerated and no grade 3 or higher KIT-related adverse events [S1].
• OLE study data indicated durable disease control in CSU and CIndU patients with 75% and 65% achieving complete or partial responses respectively, and continued favorable safety profile [S1].
• ETESIAN study in asthma demonstrated proof-of-concept with briquilimab reducing allergen-induced late asthmatic response and inflammatory markers compared to placebo, supporting further development considerations [S1].
• Jasper has an exclusive license agreement with Amgen Inc. for development and commercialization of briquilimab worldwide and a license with Stanford University for use in stem cell transplant conditioning [S1].
• The company completed the acquisition of Kira Pharmaceuticals in July 2026 and is integrating Kira's operations, which involves risks related to integration challenges, expenses, and potential disruption [S2].
• Jasper secured $132 million in financing in August 2026 to advance its post-Kira clinical pipeline [N1].
• As of June 30, 2026, Jasper had cash and cash equivalents of $7.3 million, current assets of $11.6 million, current liabilities of $7.8 million, a current ratio of 1.47, and a cash ratio of 1.37, indicating liquidity position [S2].
• The company reported a net loss of $2.76 million and basic and diluted EPS of -$0.10 for the quarter ended June 30, 2026 [S2].
• Jasper has incurred significant net losses and negative operating cash flows since inception, with an accumulated deficit of $320.6 million as of June 30, 2026, raising substantial doubt about its ability to continue as a going concern beyond one year from the 10-Q filing date [S2].
• The company plans to continue clinical development of briquilimab in mast cell driven diseases and evaluate additional indications, with future financing needs dependent on clinical progress and strategic partnerships [S2].
• Jasper announced multiple clinical milestones targeted through 2027 following the Kira acquisition [N2].
• The company has publicly reported positive clinical data for briquilimab in allergic asthma Phase 1b study and hosted webinars presenting BEACON and ETESIAN study results [N4][N5].
• RBC Capital maintained a Sector Perform recommendation on Jasper Therapeutics as of November 2025 [N6].
• Jasper conducted a $29.6 million underwritten public offering in September 2025 to raise capital [N8].